Know more about Diabetes, COVID-19 and Vaccination
30/06/2021
According to research, if people with diabetes have unsatisfactory control of their condition, such as high blood sugar, blood pressure, and cholesterol levels, obese, or suffer from complications such as heart disease, stroke, and kidney failure, he/she will have higher risk of developing serious complications during COVID-19 infection, such as using ventilator, receiving intensive care, or even death ¹.
Therefore, proper control of diabetes is extremely important to prevent complications or critical situations during disease progression. It is recommended that people with diabetes be vaccinated against influenza every year to prevent pneumonia and reduce the risk of heart disease and stroke caused by inflammation².Likewise, people with diabetes may benefit from being vaccinated against COVID-19 to reduce the risk of severe infection and damage to different organs in the body.
Professional Advice to Protect Your Health
In Hong Kong, more than 70% of deaths are caused by cancer, heart disease, stroke and pneumonia. Therefore, as many experts and officials have emphasized, the deaths that have occurred after vaccination with the COVID-19 vaccine are not directly related to vaccination.
When suffering from these diseases, many people are not diagnosed at early stage because there are no obvious symptoms, especially those with three-high risks of cardiovascular disease (i.e. high blood glucose, high blood pressure and high cholesterol).
According to a territory-wide survey from 2014 to 2015 ³, 1 in 12 adults in Hong Kong suffers from diabetes, and 1 in 3 adults suffers from obesity, high cholesterol or high blood pressure. Among them, half of them ignore their condition.
The COVID-19 pandemic and the serious consequences caused by the three-highs and diabetes have greatly reminded us of the importance of diabetes prevention. Early prevention can reduce the risk of heart disease, stroke, kidney failure and other complications and serious infections (including COVID-19)⁴.
Prevention is better than treatment – Get to Know your genetic risk for diabetes
Living with a high risk of emerging viral infections and chronic diseases, people with diabetes are a particularly vulnerable group. The risk of developing diabetes and its complications varies from person to person, in which genetics playing a key role. Although blood tests can diagnose the above conditions, they cannot rule out the possibility of future diseases.
Based on more than 20 years of clinical research and data analysis by local universities, GemVCare uses advanced patented technology and unique algorithms to help the general public assess the risk of developing diabetes or its complications in the future, so as to take early action to protect one’s health.
Precise Testing – Assess Your Risk of Diabetes and Its Complications
Combined with genetic and health data, our DForesee® calculates your risk of developing diabetes by collecting your saliva samples and taking a simple questionnaire. Personalized reports are accompanied by comprehensive health advice to help prevent diabetes and protect your health.
Click here to learn more about the DForesee® test.
Our DProtect® is specially designed for people with diabetes. It combines genetic and health data to assess whether your diabetes is properly controlled and calculates the risk of future complications. The report helps doctors determine personalized treatment plan which help effectively control and stabilize your condition and reduces the risk of developing diabetes complications.
Click here to learn more details about DProtect®.
For the sake of the health of yourself and your family, please contact us for testing immediately!
References：
-
Barron, E., Bakhai, C., Kar, P., Weaver, A., Bradley, D., et al (2020). Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. The lancet. Diabetes & endocrinology, 8(10), 813–822. https://doi.org/10.1016/S2213-8587(20)30272-2
-
Flu & People with Diabetes. (2021). Centers for Disease Control and Prevention. Retrieved from https://www.cdc.gov/flu/highrisk/diabetes.htm
-
衞生防護中心監測及流行病學處 (2017)。《二零一四至二零一五年度人口健康調查報告書》。香港特別行政區政府衞生署。取自
https://www.chp.gov.hk/files/pdf/dh_phs_2014_15_full_report_chi.pdf -
Chan, J., Lim, L. L., Wareham, N. J., Shaw, J. E., Orchard, T. J., et al (2021). The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. Lancet (London, England), 396(10267), 2019–2082. https://doi.org/10.1016/S0140-6736(20)32374-6
General Disclaimer:
The purpose of the above information is not to provide you with guidelines for vaccination against the new crown. For details about the vaccination of people with diabetes, please refer to the government’s vaccination information (https://www.covidvaccine.gov.hk/zh-HK/vaccine) or ask your family doctor.
Gemomic® Technology is a university-owned, patented technology* which utilizes genetic tests to identify subjects who may develop diabetes and suffer its resulting complications. GemVCare Limited (referred to herein as “GemVCare”) hereby expressly disclaims any and all liability as follows: Any and all data, information and result including without limitation in connection with the GemVCare services, whether medically based or otherwise, which is provided under the Gemomic® Technology or otherwise (the “Services”) shall be used for reference purpose only. The Gemomic® Technology is not intended in any shape or form to be used, construed, interpreted or applied as a substitute for professional medical care, medical advice, diagnosis, therapeutic or prophylactic which shall be provided by a doctor, physician or other qualified medical/health care professionals. The causes, treatments and consequences of diabetes and its complications are complex and multifactorial. The interactions between bio-genetic markers and other risk factors and treatments require professional interpretation for decision making. Users of the Gemomic® Technology (including without limitations to users and family members of users), who receive, believe, rely or make decisions regarding their health or medical care based on risk predictions provided by the Gemomic® Technology do so at their own risk. Users are reminded to seek professional medical care, health management or other types of advice provided by a doctor, medical practitioner, physician, qualified health care professionals or other professionals after receiving results or reports from the Gemomic® Technology and all rights arising thereof and in relation to the Services include without limitation intellectual property shall belong to GemVCare. Neither the author(s) of the published reports relating to the risk associations of genetic variants and biomarkers and other relevant reports nor GemVCare including without limitations to its shareholders, directors, employees and consultants (if any) are liable or incur any duty of care for any decisions and/or consequences arising from or in relation to the assessment and/or interpretation of the results from the Gemomic® Technology or otherwise. The provision of Services is governed by terms and conditions contained in a respective separate document which this General Disclaimer forms part of and the respective liability caps described therein shall apply with respect to GemVCare’s liability stipulated in this General Disclaimer. No part of any publication may be reproduced or transmitted in any form without the prior written permission of GemVCare. In the event of any dispute or discrepancy between the English version and the translation of other languages of this General Disclaimer, the English version shall prevail.
*Patented technology means patents and pending applications licensed from the Chinese University of Hong Kong relating to DForesee® ,DProtect® and Monogenic Diabetes Panel.